Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Reviva Pharmaceuticals (NASDAQ: RVPH ) looks to improve the standard of care treatment for schizophrenia, and is well underway to do so. The FDA requires two well-controlled trials and long-term data for that purpose. Reviva has already presented goodI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cove ...